Outcomes for systemic therapy in older patients with metastatic melanoma: Results from the Dutch Melanoma Treatment Registry

Anouk Jochems, Esther Bastiaannet, Maureen J. B. Aarts, Alexander C. J. van Akkooi, Franchette W. P. J. van den Berkmortel, Marye J. Boers-Sonderen, Alfonsus J. M. van den Eertwegh, Nienke G. de Glas, Jan Willem B. de Groot, John B. A. G. Haanen, Geke A. P. Hospers, Jacobus J. M. van der Hoeven, Djura Piersma, Rozemarijn S. van Rijn, Karijn P. M. Suijkerbuijk, Albert J. ten Tije, Astrid A. M. van der Veldt, Gerard Vreugdenhil, Michiel C. T. van Zeijl, Ellen KapiteijnMichel W. J. M. Wouters

Research output: Contribution to journalArticleAcademicpeer-review

2 Citations (Scopus)


Background: The incidence of metastatic melanoma is increasing in all ages. Multiple trials with targeted drugs and immune checkpoint inhibitors showed improved survival in metastatic melanoma. However, patients aged ≥75 years are often under-represented in clinical trials, therefore raising questions on safety and efficacy of treatment. Patients and methods: We analyzed a real-world cohort of 3054 patients with metastatic melanoma stratified for age (≤65 years, 66–74 years and ≥ 75 years), and BRAF status, providing data on treatment strategies, toxicity, and survival. Kaplan Meier curves and Cox Proportional Hazard Models were used to present overall survival (OS) and Melanoma Specific Survival (MSS). Results: Overall, 52.2% of patients were ≤ 65 years and 18.4% of patients ≥75 years. BRAF mutated tumors were found less often in patients ≥75 years: 34.5% versus 65% in patients ≤65 years. Patients ≥75 years received systemic therapy less frequently compared to their younger counterparts independent of the BRAF status. When receiving treatment, no statistical significant difference in grade 3 or 4 toxicity was observed. Three year Overall Survival rate was 13.7% (9.1–19.3) in patients ≥75 years versus 26.7% (23.1–30.4) in patients ≤65 years, with a Hazard Ratio (HR) of 1.71 (95%CI 1.50–1.95), p < 0.001. Three year Melanoma Specific Survival was 30.4% (22.0–39.2) versus 34.0% (29.7–38.2), HR 1.26 (95% CI 1.07–1.49), p = 0.005 with an adjusted HR of 1.21 (1.00–1.47), p = 0.049. Conclusion: Patients with metastatic melanoma ≥75 years are less frequently treated, but when treated there is no statistical significant increase in toxicity and only a borderline statistical significant difference in Melanoma Specific Survival was seen, compared to younger patients.

Original languageEnglish
Pages (from-to)1031-1038
Number of pages8
JournalJournal of geriatric oncology
Issue number7
Early online date2021
Publication statusPublished - Sept 2021


  • Immune checkpoint inhibitors
  • Metastatic melanoma
  • Older patients
  • Outcome
  • Safety
  • Targeted therapy

Cite this